Noscapine

Natural Products

Apoptosis; Opioid Receptor

-20°C, 3 years; 4°C, 2 years (Powder)

Noscapine ((S, R)-Noscapine) is an orally active phthalideisoquinoline alkaloid with potent antitussive. Noscapine exerts its antitussive effects by activating sigma opioid receptors and is a non-competitive Bradykinin inhibitor. Noscapine disrupts microtubule dynamics, induces mitotic arrest and apoptosis. Noscapine possesses anticancer, neuroprotective, anti-inflammatory activities, and can cross the blood-brain barrier[1][2][3][4][5].

DMSO: ≥ 30 mg/mL

Noscapine ((S, R)-Noscapine) is an orally active phthalideisoquinoline alkaloid with potent antitussive. Noscapine exerts its antitussive effects by activating sigma opioid receptors and is a non-competitive Bradykinin inhibitor. Noscapine disrupts microtubule dynamics, induces mitotic arrest and apoptosis. Noscapine possesses anticancer, neuroprotective, anti-inflammatory activities, and can crosse the blood-brain barrier^{[1][2][3][4][5]}.
IC50 & Target: Sigma opioid receptors^[4]
Bradykinin^[5]
Apoptosis^[1]
In Vitro: Noscapine (0-1000 uM; 0-96 hours; rat C6 glioma cells) treatment inhibits cell viability of rat C6 glioma in vitro in a dose- and time-dependent manner. Noscapine inhibits the viability of rat C6 glioma cells with an IC₅₀ of 250 uM at 72 hours^[1].

Noscapine exposure causes abnormal S-phase reentry, increases mitotic arrest and results in excessive DNA accumulation^[1].

Cylindromatosis increases the ability of noscapine to induce mitotic arrest and apoptosis. Cylindromatosis enhances the effect of noscapine on microtubule polymerization and promotes noscapine binding to microtubules^[2].
In Vivo: Noscapine (300?mg/kg; oral gavage; daily; for 15 days; athymic female mice) treatment reduces tumor growth in mice^[1].